Which company develops and produces Sparsentine?

sparsentan is a drug developed and produced by the American biopharmaceutical company Gilead Sciences (Gilead Sciences). Sparsentanis the first non-immunosuppressive therapy for IgA nephrotic proteinuria. Sparsentanmay reduce primary immunoglobulinAnephropathy (I gAN) Proteinuria in adults, usually urine protein to creatinine ratio (UPCR) ≥1.5g/g5.

The binding rate of sparsentane to human plasma proteins is over 99%. Sparsentanis mainly metabolized by cytochrome P450 3A. Sparsentine is primarily excreted in feces and urine. After giving a single dose (400 mg) radiolabeled sparsentane in healthy subjects, approximately 80% of the dose was recovered in the feces (9% unchanged) and 2% was recovered in the urine (a negligible amount unchanged). During the 10 day collection period, 82% of the dosed radioactivity was recovered. The half-life of sparsentineat steady state is estimated to be 9.6 hours. Sparsentan has a time-dependent clearance, possibly due to its induction of its own metabolism over time. After an initial dose of 400 mg, the apparent clearance of sparsentane is 3.88 L/h. At steady state, the apparent clearance increases to 5.11 L/h.

After single doses of 200-1600mg, C was maximal and the AUC of sparsentan increased in a less than dose-proportional manner. Sparsentan has time-dependent pharmacokinetics, possibly due to its induction of its own metabolism over time, with it reaching steady-state plasma levels within 7 days at approved recommended doses. After a single oral dose of 400mg, the maximum C, AUC and median time to peak plasma concentration were 6.97 μg/mL respectively., 83 μg×h/mL and 3 hours. After daily administration of 400mg of Basentan, the maximum steady-state C was 6.47 μg/mL, and the AUC was 63.6 μg×h/mL. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.